LIA
SRPT icon

LS Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

LS Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-484
Closed -$62K – 1740
2019
Q4 		$62K Hold
484
– – ﹤0.01% 1262
2019
Q3 		$36K Buy
+484
New +$57.2K ﹤0.01% 1386

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

LS Investment Advisors's SRPT Position: Q1 2020 in Review

LS Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2020, closing a stake of 484 shares — an estimated $62K sold.

LS Investment Advisors first reported a position in SRPT in Q3 2019 and held it in 2 quarters. The position peaked at $62K in Q4 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

  • LS Investment Advisors reported no remaining Sarepta Therapeutics position as of Q1 2020 after selling out during the quarter.
  • LS Investment Advisors sold 484 Sarepta Therapeutics shares in Q1 2020, an estimated $62K.
  • LS Investment Advisors first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 2 quarters.
  • LS Investment Advisors's Sarepta Therapeutics position peaked at $62K in Q4 2019.
  • 365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on LS Investment Advisors's 13F filing for Q1 2020, filed 20 Apr 2020.